As a future direction, the better survival advantage for DLBCL patients with a c-Rel signature could be examined with regard to both sensitivity toward apoptosis under classical therapeutic molecules and the ability of tumor cells to be eliminated by the immune microenvironment. This evidence concerns the gene REL and diffuse large B-cell lymphoma.